Cargando…
Neo‐Antigen‐Reactive T Cells Immunotherapy for Colorectal Cancer: A More Personalized Cancer Therapy Approach
Colorectal cancer (CRC) is the second most common malignancy in women and the third most frequent cancer in men. Evidence has revealed that the survival of patients with metastatic CRC is very low, between one and three years. Neoantigens are known proteins encoded by mutations in tumor cells. It is...
Autores principales: | Chen, Guan‐Liang, Kong, De‐Xia, Lin, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632666/ https://www.ncbi.nlm.nih.gov/pubmed/37970536 http://dx.doi.org/10.1002/gch2.202200186 |
Ejemplares similares
-
Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies
por: Randrian, Violaine, et al.
Publicado: (2021) -
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy
por: Parmiani, Giorgio, et al.
Publicado: (2015) -
Colorectal Cancer in the Elderly Patient: The Role of Neo-adjuvant Therapy
por: Dodaro, Concetta Anna, et al.
Publicado: (2019) -
A computational workflow for predicting cancer neo-antigens
por: Kasaragod, Sandeep, et al.
Publicado: (2022) -
MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy
por: Baleeiro, Renato B., et al.
Publicado: (2022)